Billable / Specific Code
ICD-10-CM D61.810 is the diagnosis code for Antineoplastic chemotherapy induced pancytopenia. This code falls under the section "Aplastic and other anemias and other bone marrow failure syndromes" within Chapter 3 â Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89). It is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Medical coders and healthcare providers use this code to document and classify diagnoses in electronic health records, insurance claims, and clinical databases.
The following conditions are not included in D61.810. If the patient has both, code each condition separately:
Understanding where D61.810 sits in the ICD-10-CM classification helps ensure proper coding:
Yes, D61.810 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
D61.810 is the ICD-10-CM diagnosis code for "Antineoplastic chemotherapy induced pancytopenia". It is used by healthcare providers to classify and document this condition in medical records and insurance claims.
The parent code of D61.810 is D61.81 ("Pancytopenia"). D61.810 provides a more specific classification within this category.
D61.810 is located in Section D60-D64 â "Aplastic and other anemias and other bone marrow failure syndromes" within Chapter 3 of the ICD-10-CM Tabular List.
Use D61.810 when the patients documented diagnosis matches "Antineoplastic chemotherapy induced pancytopenia" and the clinical documentation supports this level of specificity. Always verify with the latest ICD-10-CM guidelines and payer requirements.
The ICD-10-CM code for Antineoplastic chemotherapy induced pancytopenia is D61.810.
Yes, D61.810 can be used as a primary diagnosis code since it is billable and specific.
D61.810 is in Chapter 3 of the ICD-10-CM Tabular List.
Yes, D61.810 is a valid ICD-10-CM code for the 2026 fiscal year, subject to official CMS updates.